title: Serum-soluble interleukin-2 receptor concentrations in patients with gastric cancer.
abstract: BACKGROUND
  Serum concentrations of soluble interleukin-2 receptor (IL-2R) were found to be high in patients with autoimmune diseases, lung cancer, malignant lymphoma, tuberculosis, and other diseases. Serum-soluble IL-2R was evaluated as a tumor maker in patients with gastric cancer.
  
  
  METHODS
  Preoperative concentrations of serum-soluble IL-2R were examined in 40 patients with gastric cancer. The authors investigated the correlations of serum-soluble IL-2R concentrations with various characteristics of this cancer (disease stage, gross appearance, depth of the tumor, lymph node metastasis, liver metastasis, peritoneal metastasis, histopathologic grade, serum carcinoembryonic antigen (CEA), alpha-fetoprotein (alpha-FTP), carbohydrate antigen 19-9 (CA19-9), and immunosuppressive acidic protein (IAP). Serum soluble IL-2R concentrations were measured with an enzyme-linked immunosorbent assay.
  
  
  RESULTS
  Levels of serum-soluble IL-2R in patients with gastric cancer were significantly higher than those of normal control subjects. Serum concentrations of IL-2R in patients with lymph node metastasis were also significantly higher than those of patients without lymph node metastasis. There were no significant differences in histopathologic findings (grade, lymphatic invasion, venous invasion). Moreover, serum concentrations of soluble IL-2R in patients who were IAP positive were significantly higher than those who were IAP negative.
  
  
  CONCLUSIONS
  Preoperative serum-soluble IL-2R concentrations in patients with gastric cancer reflect the occurrence of regional lymph node metastases. Preoperative evaluation of serum soluble IL-2R concentrations may be a valuable parameter of indicating the probability of lymph node metastasis preoperatively.
authors.affiliation: Second Department of Surgery, Saitama Medical School, Saitama, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Murakami
authors.forename: A
authors.initials: A
authors.lastname: Satomi
authors.forename: K
authors.initials: K
authors.lastname: Ishida
authors.forename: H
authors.initials: H
authors.lastname: Murai
authors.forename: M
authors.initials: M
authors.lastname: Matsuki
authors.forename: T
authors.initials: T
authors.lastname: Hashimoto
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000704:Analysis of Variance; D018395:CA-19-9 Antigen / Q000097:blood; D002272:Carcinoembryonic Antigen / Q000097:blood; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009363:Neoplasm Proteins / Q000097:blood; D009367:Neoplasm Staging; D015375:Receptors, Interleukin-2 / Q000378:metabolism*; D013274:Stomach Neoplasms / Q000097:blood* / Q000276:immunology / Q000473:pathology; D000509:alpha-Fetoproteins / Q000378:metabolism
chemical_list: D018395:CA-19-9 Antigen; D002272:Carcinoembryonic Antigen; D009363:Neoplasm Proteins; D015375:Receptors, Interleukin-2; D000509:alpha-Fetoproteins; C030193:immunosuppressive acidic protein